文献速递中医妇科中药与中成药合理使用

桂枝茯苓丸低剂量与常规剂量治疗症状性子宫肌瘤的随机双盲试验

Randomized double-blind trial comparing low dose and conventional dose of a modified traditional herbal formula Guizhi Fuling Wan in women with symptomatic uterine fibroids.
PubMed 文献 · J Ethnopharmacol · 2021-09-22

两组在终点时除中医证候评分外其余结局组间无显著差异,但两组症状严重度、盆腔疼痛功能影响、中医证候评分及肌瘤体积和子宫MRI状况较基线均显著改善(p<0.05),低剂量组中医证候评分改善优于常规剂量组(p=0.024),未发生与干预相关的严重不良事件。

要点

  • 改良桂枝茯苓丸低剂量与常规剂量均可显著改善子宫肌瘤相关症状及肌瘤体积。
  • 两组间除中医证候评分外,终点时所有结局无显著差异。
  • 低剂量组中医证候评分改善优于常规剂量组(p=0.024),未发生相关严重不良事件。

核心结论

  • 低剂量与常规剂量改良桂枝茯苓丸均能显著改善子宫肌瘤相关症状和肌瘤体积,但两组间无显著差异。
  • 该方在子宫肌瘤女性中安全性良好。

研究设计与样本

  • 随机双盲、剂量对照试验,在香港中医门诊开展。
  • 随机分两组,每日服用改良桂枝茯苓丸低剂量或常规剂量,疗程16周。
  • 研究由数据安全监查委员会进行质量控制。

主要发现

  • 终点时组间比较除中医证候评分外所有结局均无显著差异。
  • 终点时两组症状严重度、盆腔疼痛功能影响、中医证候评分、MRI肌瘤体积及子宫状况较基线均显著改善(p<0.05)。
  • 低剂量组中医证候评分终点改善优于常规剂量组(p=0.024)。
  • 未观察到与干预相关的严重不良事件。

关键数值与推荐

  • 主要结局为子宫肌瘤症状-生活质量问卷测量的症状严重度。
  • 次要结局包括生活质量、月经出血(图示失血量评估图表)、疼痛严重度(6点行为评定量表)、中医证候评分、MRI肌瘤体积、血红蛋白及激素水平。

临床怎么用

  • 改良桂枝茯苓丸可用于症状性子宫肌瘤女性,低剂量与常规剂量均有效且安全。
  • 低剂量在改善中医证候评分方面可能更具优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: The herbal formula Guizhi Fuling Wan is one common remedy for treating uterine fibroids (UFs) and the relevant symptoms in Traditional Chinese Medicine (TCM). Previous systematic reviews showed that Guizhi Fuling Formula appeared to have additional benefit based on mifepristone treatment in reducing volume of fibroids. AIM OF STUDY: To study the efficacy and safety of the conventional dose of a modified herbal formula Guizhi Fuling Wan in patients with symptomatic uterine fibroids in comparison with a sub-effective dose control. MATERIALS AND METHODS: This randomized double-blind, dosage-controlled trial was carried out in an outpatient clinic of traditional Chinese medicine in Hong Kong. Women with symptomatic uterine fibroids diagnosed according to the WHO International Classification of Diseases (ICD-10) were recruited and randomly assigned to one of two groups that received modified Guizhi Fuling Wan at either a low dose or the conventional dose on a daily basis for 16 weeks. This study was quality controlled by a data safety monitoring board. The primary outcome was the symptom severity as measured with the Uterine Fibroid Symptom-Quality of Life questionnaire. The secondary outcomes included quality of life, menstrual bleeding (measured on a pictorial blood loss assessment chart), pain severity (measured on the 6-point behavioral rating scale), change in Chinese medicine syndrome score, fibroid volume (measured by magnetic resonance imaging), hemoglobin level, and hormone levels. RESULTS: Seventy-eight women were recruited for this study. Between-groups comparison showed no significant difference at the endpoint for all outcomes except for the Chinese medicine syndrome score; however, at the endpoint, within-group comparison showed significant improvement in both groups relative to baseline in symptom severity, functional influence of pelvic pain, Chinese medicine syndrome score, and fibroid volume and uterus condition on magnetic resonance imaging (p < 0.05).The low-dose group yielded greater endpoint improvement in the Chinese medicine syndrome score than the conventional-dose group (p=0.024). No serious adverse events related to the intervention were noted. CONCLUSION: Both low-dose and conventional-dose preparations significantly ameliorated uterine fibroid-related symptoms and fibroid volume, although no significant difference was found between the low-dose and conventional-dose groups. The herbal formula GuizhiFuling Wan is safe in women with uterine fibroids.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Meng W, Lin WL, Yeung WF, et al. Randomized double-blind trial comparing low dose and conventional dose of a modified traditional herbal formula Guizhi Fuling Wan in women with symptomatic uterine fibroids. J Ethnopharmacol. 2021. PMID: 34562564. doi:10.1016/j.jep.2021.114676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。